Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Clomipramine

Detailed information about Clomipramine

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age.

What to watch for:

  • Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian
  • CLOMICALM Tablets should not be used in male breeding dogs
  • CLOMICALM Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz]
  • CLOMICALM Tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold
  • very low energy (1 reports)
  • Other abnormal test result NOS (1 reports)
  • Lameness (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian
  • CLOMICALM Tablets should not be used in male breeding dogs
  • CLOMICALM Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz]
  • CLOMICALM Tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold
  • very low energy

Most reported reactions:

  • Tiredness (lethargy) (1 reports)
  • Other abnormal test result NOS (1 reports)
  • Lameness (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:01 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 7, 2026, 11:03 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Image coming soon
Clomipramine

Clomipramine

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Tablet
Identifiers:
ANADA: 200635 ANADA: 200825 NADA: 141120 NDC Package: 11695-6950-3 NDC Package: 11695-6951-3 NDC Package: 11695-6952-3 NDC Package: 11695-6953-3 NDC Package: 13985-974-30 NDC Package: 13985-975-30 NDC Package: 13985-976-30 NDC Package: 13985-977-30 NDC Package: 46066-131-36 NDC Package: 46066-132-36 NDC Package: 46066-133-36 NDC Package: 46066-134-36 NDC Package: 51311-140-05 NDC Package: 51311-141-20 NDC Package: 51311-142-80 NDC Package: 86039-113-30 NDC Package: 86039-114-30
Source metadata:

Warnings / Contraindications

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. CLOMICALM Tablets should not be used in male breeding dogs. CLOMICALM Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz]. CLOMICALM Tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold.

  • High: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. CLOMICALM Tablets should not be used in male breeding dogs. CLOMICALM Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz]. CLOMICALM Tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
16
Species represented
2
Grouped by Body System
Digestive (3) · Vomiting, Decreased appetite, Appetite loss Neurologic (3) · Unsteady walking (ataxia), Tiredness (lethargy), Head tilt - neurological disorder Behavior (1) · Behavioral disorder (unspecified) Effectiveness (1) · Lack of efficacy - NOS Other (24) · Vestibular disorder NOS, Sleepiness - systemic disorder, Self mutilation
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1

Species coverage: Dog (19) Cat (13)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Non-serious - 1
Other Dog Non-serious - 1
Neurologic Dog Non-serious - 1
Neurologic Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Effectiveness Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Neurologic Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Behavior Dog Non-serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (0)
  • No official label or package insert links yet.
SPL (3)
  • Clomipramine Hydrochloride Tablets · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17969/Clomipramine%20Hydrochloride%20Tablets
  • CLOMICALM® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1826/CLOMICALM%C2%AE
  • Clomipramine Hydrochloride Tablets · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/7890/Clomipramine%20Hydrochloride%20Tablets
FOI (4)
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 7, 2026, 11:03 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: CLOMICALM® Clomipramine Hydrochloride Tablets
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Tablet • Oral
Applications: ANADA 200-825 • NADA 141-120 • ANADA 200-635
Documents: 4 (FOI: 4) • SPL: 3 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 14 • Cat 8 • View
Case summaries: 10 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. CLOMICALM Tablets should not be used in male breeding dogs. CLOMICALM Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz]. CLOMICALM Tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold. (Contraindication, High)
Top reaction signals
Tiredness (lethargy) (1) Other abnormal test result NOS (1) Lameness (1) Knuckling (1) Ketosis (1) Hind limb paresis (1) Elevated globulins (1) Elevated creatinine (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200635 ANADA: 200825 NADA: 141120 NDC Package: 11695-6950-3 NDC Package: 11695-6951-3 NDC Package: 11695-6952-3 NDC Package: 11695-6953-3 NDC Package: 13985-974-30 NDC Package: 13985-975-30 NDC Package: 13985-976-30 NDC Package: 13985-977-30 NDC Package: 46066-131-36 NDC Package: 46066-132-36 NDC Package: 46066-133-36 NDC Package: 46066-134-36 NDC Package: 51311-140-05 NDC Package: 51311-141-20 NDC Package: 51311-142-80 NDC Package: 86039-113-30 NDC Package: 86039-114-30 NDC Package: 86039-115-30 NDC Package: 86039-116-30 NDC Package: 86101-035-30 NDC Package: 86101-036-30
Package NDC Product NDC Form / Route Status
11695-6950-3 11695 -
11695-6951-3 11695 -
11695-6952-3 11695 -
11695-6953-3 11695 -
13985-974-30 13985 -
13985-975-30 13985 -
13985-976-30 13985 -
13985-977-30 13985 -
46066-131-36 46066 -
46066-132-36 46066 -
46066-133-36 46066 -
46066-134-36 46066 -
51311-140-05 51311 -
51311-141-20 51311 -
51311-142-80 51311 -
86039-113-30 86039 -
86039-114-30 86039 -
86039-115-30 86039 -
86039-116-30 86039 -
86101-035-30 86101 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 7 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. CLOMICALM Tablets should not be used in male breeding dogs. CLOMICA… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Underdo… (Official, 2026-02-12)
  • usage: CLOMICALM Tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. Clo… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Clomipramine Hydrochloride Tablets
RX
Clomipramine Hydrochloride
Tablet • Oral
Label highlights
Official documents
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-825 Approved Nov 3, 2025
CLOMICALM®
RX
Clomipramine Hydrochloride
Tablet • Oral
Label highlights
Official documents
Virbac AH, Inc. NADA 141-120 Approved Mar 12, 2025
Clomipramine Hydrochloride Tablets
RX
Clomipramine Hydrochloride
Tablet • Oral
Label highlights
Official documents
Mizner Bioscience LLC ANADA 200-635 Approved Nov 1, 2019

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
5 mg, 20 mg, 40 mg, and 80 mg
Dogs
Indication

For use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age.

Dosage

2 to 4 milligrams of clomipramine hydrochloride per kilogram (0.9 to 1.8 milligrams per pound) of body weight per day, administered as a single daily dose or divided twice daily.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains 5, 20, 40, or 80 milligrams of clomipramine hydrochloride.
Dogs (6 Months of Age and Older)
Indication
CLOMICALM Tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age.
Dosage
2 to 4 milligrams of clomipramine hydrochloride per kilogram (0.9 to 1.8 milligrams per pound) of body weight per day, administered as a single daily dose or divided twice daily.
Limitations
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. CLOMICALM Tablets should not be used in male breeding dogs. CLOMICALM Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz]. CLOMICALM Tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
5 mg, 20 mg, 40 mg, and 80 mg
Dogs
Indication

Clomipramine Hydrochloride Tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than
6 months of age.

Dosage

The recommended daily dose of Clomipramine Hydrochloride Tablets is 2 to 4 mg/kg/day (0.9 – 1.8 mg/lb/day). It can be administered as a single daily dose or divided twice daily based on patient response and/or
tolerance of the side effects.

Limitations

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    This supplement provides for the addition of a 5 mg tablet size.
  • Summary
    To be used apart of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

CLOMICALM Tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. Clomipramine Hydrochloride Tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. For use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. CLOMICALM Tablets should not be used in male breeding dogs. CLOMICALM Tablets should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g., selegiline hydrochloride (L-deprenyl), amitraz]. CLOMICALM Tablets are contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Decreased appetite (1) • Dog Appetite loss (1) • Cat

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog Tiredness (1) • Dog Head tilt - neurological disorder (1) • Dog

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Dog

Showing top 5 for Behavior.

Effectiveness
Lack of efficacy - NOS (1) • Cat

Showing top 5 for Effectiveness.

Other
Vestibular disorder NOS (1) • Dog Sleepiness - systemic disorder (1) • Dog Self mutilation (1) • Cat Reduced responses (1) • Dog Proprioception deficit (1) • Dog
Show more (19)
Other abnormal test result NOS (1) • Cat Nystagmus (1) • Dog Lameness (1) • Cat Knuckling (1) • Cat Ketosis (1) • Cat Hypotension (1) • Dog Hind limb paresis (1) • Cat Elevated globulins (1) • Cat Elevated creatinine (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated alanine aminotransferase (1) • Cat Dull (1) • Dog Diabetic ketoacidosis (1) • Cat Depressed reflexes (1) • Cat Death by euthanasia (1) • Cat Death (1) • Dog Bradycardia (1) • Dog Abnormal ultrasound finding (1) • Dog Abnormal electrocardiogram (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Beagle, Mixed, 7.3 kilogram • Drug: MSK, Tablet, Oral • Reactions: Sleepiness - systemic disorder, Hypotension, Bradycardia, Vomiting, Abnormal electrocardiogram… • Outcome: Recovered/Normal

  • Report ID: FIN-USFDACVM-2025-FI-000002
  • Serious AE: No
  • Treated For AE: No
  • Sex: Mixed
  • Weight: 7.300 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Sleepiness - systemic disorder Hypotension Bradycardia Vomiting Abnormal electrocardiogram Unsteady walking (ataxia) Reduced responses
Outcomes: Recovered/Normal

Dog, Terrier - Yorkshire, Male, 10 year, 3.8 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 dose per animal • Reactions: Lack of efficacy - NOS, Weight loss, Tiredness (lethargy), Decreased appetite, Elevated creatinine… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-028470
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 3.800 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 dose per animal
Reactions Reported:
Lack of efficacy - NOS Weight loss Tiredness (lethargy) Decreased appetite Elevated creatinine Elevated blood urea nitrogen Abnormal ultrasound finding
Outcomes: Outcome Unknown

Dog, Bulldog - French, Male, 8 year, 13.68 kilogram • Drug: MSK, Tablet, Oral, Dose: 40 Milligram per animal, Frequency: 1 per day • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-030539
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 8.00 Year
  • Weight: 13.680 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 40 Milligram per animal
  • Frequency: 1 per day
Reactions Reported:
Death
Outcomes: Died

Dog, Shepherd Dog - German, Male, 9 year, 35 kilogram • Drug: MSK, Oral • Reactions: Vestibular disorder NOS, Nystagmus, Proprioception deficit, Unsteady walking (ataxia), Dull… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-017653
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 35.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Vestibular disorder NOS Nystagmus Proprioception deficit Unsteady walking (ataxia) Dull Head tilt - neurological disorder Behavioral disorder (unspecified) Other abnormal test result NOS
Outcomes: Ongoing

Dog, ['Crossbred Canine/dog', 'Shepherd Dog - German'], Male, 9 year, 35 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Vestibular disorder NOS, Nystagmus, Proprioception deficit, Unsteady walking (ataxia), Dull… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-013287
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 35.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Vestibular disorder NOS Nystagmus Proprioception deficit Unsteady walking (ataxia) Dull Head tilt - neurological disorder Behavioral disorder (unspecified)
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 9 year, 6.849 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Lack of efficacy - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2024-US-018682
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 6.849 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Lack of efficacy - NOS
Outcomes: Ongoing

Cat, Domestic Mediumhair, Male, 6 year, 5.761 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Self mutilation • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2024-US-017229
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 6.00 Year
  • Weight: 5.761 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Self mutilation
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Male, 7 year, 4.8 kilogram • Drug: MSK, Unknown • Reactions: Appetite loss, Elevated alanine aminotransferase, Ketosis, Elevated globulins, Diabetic ketoacidosis… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2023-US-037931
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 7.00 Year
  • Weight: 4.800 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Appetite loss Elevated alanine aminotransferase Ketosis Elevated globulins Diabetic ketoacidosis Weight loss Other abnormal test result NOS
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.